Eli Lilly (NYSE:LLY) received U.S. FDA approval for an expanded indication of Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk.
Eli Lilly (NYSE:LLY) announced that its board of directors has declared a cash dividend of $1.73 per share on outstanding common stock for the third quarter of 2026.
Eli Lilly (NYSE:LLY) has completed its acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders.
Eli Lilly and Company (NYSE:LLY) filed six lawsuits against U.S. businesses accused of selling black-market retatrutide products, while the company continues efforts to report illegal sales to regulators and law enforcement.
Eli Lilly (NYSE:LLY) announced positive topline Phase 3 results for its investigational triple agonist, retatrutide, from the 80-week TRIUMPH-2 and TRIUMPH-3 clinical trials.
